AIRFLOW 3 Clinical Trial

The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

Image of AIRFLOW 3 Clinical Trial logo


The study purpose is Treatment.


COPD stands for chronic obstructive pulmonary disease. COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. The most common COPDs are emphysema and chronic bronchitis. Air gets trapped in the lungs, and breathing it out is difficult. Symptoms include breathing difficulty, cough, mucus (sputum) production, and wheezing. Targeted lung denervation (TLD) is a novel therapy for COPD. TLD works by disrupting the activity of a certain nerve in the lungs. The study focuses on patients with CPOD. The goal is to confirm the safety and efficacy of TLD.

AIRFLOW 3 Trial Brochure

Find out more information about this clinical trial and if you meet the requirements.
Download The Brochure

Contact Us

For more information on this trial and to see if you qualify, please call us at 512-819-0132.